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1. INTRODUCTION 
Inhibitor- 1 is a small heat-stable protein first de- 
scribed by Huang and Glinsmann [l] that is a spe- 
cific inhibitor of protein phosphatase-1 [2,3]. This 
enzyme is the major protein phosphatase involved 
in the regulation of glycogen metabolism in skele- 
tal muscle [2-51, but its broad tissue distribution 
and ability to dephosphorylate enzymes involved 
in the regulation of glycolysis, fatty acid synthesis, 
cholesterol synthesis and protein synthesis suggests 
a wider role in metabolic regulation [3-61. 
Inhibitor- 1 is only active after phosphorylation 
by cyclic AMP-dependent protein kinase [l] on a 
threonine 171 35 residues form the N-terminus [8]. 
It is therefore a novel protein in metabolic regula- 
tion that can mediate the control of a protein phos- 
phatase by a protein kinase. The phosphorylation 
of inhibitor-l in mammalian skeletal muscle in- 
creases in response to adrenalin [9] and decreases 
in response to insulin [lo]. The latter is due to sup- 
pression of the effects of low concentrations of the 
/?-adrenergic agonist isoproterenol [ 111. These ob- 
servations suggest that inhibitor- 1 may play an im- 
portant role in the hormonal control of glycogen 
metabolism and other cellular processes in which 
protein phosphatase- 1 participates. 
The phosphorylated form of inhibitor-l is a 
non-competitive inhibitor [12] that is effective at 
nM levels, while the dephosphorylated form is 
completely inactive [ 121. The physico-chemical 
properties of inhibitor-l are unusual. It has a very 
*To whom correspondence should be addressed 
low content of hydrophobic amino acids [8], pos- 
sesses little ordered structure [ 131 and its activity is 
extremely stable to heat, exposure to low pH, 
organic solvents and detergents [ 1,8,9]. These ob- 
servations suggest that the activity of inhibitor-l 
might be determined by some feature of the prim- 
ary structure, rather than the tertiary structure of 
the protein, a view supported by the isolation of a 
65-residue CNBr peptide, containing threonine-35, 
that retained full activity [14]. However, a de- 
capeptide, also containing threonine-35, was inac- 
tive [7]. 
We have determined the complete primary 
structure of inhibitor-l and shown that it com- 
prises 165 residues [8]. During the course of this 
analysis a large number of peptides containing 
threonine-35 were generated and tested for their 
ability to inhibit protein phosphatase-1. These re- 
sults demonstrate that a hydrophobic region con- 
taining residues 9-22 is essential for the activity of 
inhibitor-l, in addition to the phosphorylation of 
threonine-35. A region between residues 42-54 
may also be essential for activity. 
2. MATERIALS AND METHODS 
2.1. Protein preparations 
32P-Labelled inhibitor- 1 (81, 32P-labelled phos- 
phorylase a [ 151 and protein phosphatase-1 [ 151 
were isolated by published procedures. Proteinases 
and other materials were obtained from the 
sources given in [S]. 
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Table 1 
Amino acid composition of32P-labelled subfragments of inhibitor-l containing 
phosphothreonine-35 
October 1982 
Amino acid 
Aspartic acid 
asparagine 
Threonine 
Serine 
Glutamic acid 
glutamine 
Proline 
Glycine 
Alanine 
Valine 
Isoleucine 
Leucine 
Phenylalanine 
Histidine 
Lysine 
Arginine 
Total 
Position in sequence 
Llc 
5.3(5) 
3.8(4) 
3.3(3) 
9.1(8) 
8.2(8) 
3.0(3) 
2.7(3) 
2.5(3) 
7.4(7) 
0.93( 1) 
1.1(l) 
1.1(l) 
4.8(5) 
52 
9-60 
LlcA 
3.9(4) 
2.4(3) 
3.0(3) 
6.4(6) 
5.7(6) 5.2(6) 4.2(4) 
3.1(3) 
2.1(2) 
2.2(2) 
4.1(4) 
4.5(5) 
38 
23-60 
Llb LlbA 
3.3(4) 2.3(3) 
3.4(4) 3.1(3) 
4.4( 3) 2.6(3) 
8.1(8) 5.8(6) 
3.3(3) 
2.8(3) 
1.5(2) 
4.3( 5) 
0.88( 1) 
0.97( 1) 
0.94( 1) 
5.0(5) 
46 
9-54 
3.7(3) 
2.1(2) 
1.1(l) 
2.4(2) 
4.7(5) 
32 
23-54 
Bl Chl 
1.6(2) 2.4( 1) 
3.2(2-3) 
1.9(O) 
4.9(4) 
2.2(2) 5.1(4-5) 
2.4(O) 
1.2(l) 3.7(3) 
1.7(0-2) 
l.O( 1) 0.74( 1) 
1.2( 1) 3.6(3-5) 
0.34( 1) 
4.1(4) 3.8(4) 
I1 23-29 
29-39 13/ 17-39141 
Peptides Llb and Llc obtained from inhibitor-l by digestion with the lysine-specific 
proteinase, were cleaved to peptides LlbA and LlcA, respectively, by incubation at 
pH 2.9. Peptide BI was obtained by subtilisin digestion of Llb/Llc and peptide Chl 
by chymotrypsin digestion of peptide CB-1 (see section 2). The numbers in parenthesis 
indicate residues present in the sequence. Serine and glycine in peptide Chl were 
contaminating amino acids from thin-layer peptide mapping. The first glycine residue 
in inhibitor- I is at residue-93 
2.2. Isolation of -‘2P_labelledpeptides from 
inhibitor-l 
Digestion of inhibitor-l with the proteinase 
from the fungus Armillaria mellea that cleaves 
specifically on the N-terminal side of lysine resi- 
dues, termed ‘lysine-specific proteinase’, generates 
I I 
40 50 60 
fraction number 
Fig.1. A fraction containing peptide Llb (40 nmol) and 
Llc (IO nmol) was incubated at pH 2.9 for 48 h as in 
section 2 and chromatographed on an Altex model 334 
HPLC system using a Waters pbondapak C,, reverse- 
phase HPLC column (30 cm X 3.9 mm). A linear gra- 
dient of O-55% acetonitrile/water containing 0.1% tri- 
fluoroacetic acid was employed at 1.0 ml/min. Fractions 
of 0.5 ml were collected: (e-4) s2P-radioactivity (Ceren- 
kov counting); (-) absorbance at 210 nm. The 
acetonitrile gradient is illustrated by the diagonal line. 
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a major [j*P]peptide Llc comprising residues 9-60 
and two minor [3*P]peptides Ll b and Lld com- 
prising residues 9-54 and 33-60, respectively. The 
latter peptides arise from anomalous cleavage of 
Arg-Ile and Arg-Arg bonds, respectively [S]. A 
fraction containing peptide Ll b (40 nmol) and L lc 
(10 nmol) was incubated for 48 h at 40°C in 1.0 M 
acetic acid, adjusted to pH 2.9 with pyridine. This 
dilute acid treatment produced -70% cleavage of 
the Asp**-Prd3 bond of inhibitor-l [B]. The 
cleavage products and undigested peptides were 
purified by HPLC (fig.1) and their compositions 
are given in table 1. Peptides Llb/Llc (BOnmol) 
were also digested with subtilisin for 1 h at 37°C in 
0.1 M N-ethyl morpholine acetate buffer (pH 8.5) 
at a weight ratio of proteinase: substrate of 1: 100. 
The 3*P-labelled fragment (peptide Bl) was pu- 
rified by HPLC as in tig.1, and its composition is 
also given in table 1. 
The active CNBr peptide CB-1 (residues 2-66, 
2 mg) was digested with chymotrypsin for 1 h at 
37°C in 0.05 M ammonium bicarbonate (pH 7.8) 
at a weight ratio of proteinase:substrate of 1:50. 
The 3*P-labelled peptide (termed Chl) was iso- 
lated by gel filtration on Sephadex G-50 superfine 
and two dimensional peptide mapping. Automated 
sequencer analysis indicated that peptide Chl con- 
tained equal amounts of 2 peptides: one com- 
mencing at residue 13; the other at residue 17 of 
inhibitor-l (not shown). The composition of the 
peptide (table 1) indicated that it terminated at 
residue(s) 39-4 1. 
The isolation of other [3*P]peptides from inhibi- 
tor-l are given in IS]. 
2.3. Assay of inhibitor-l and its subfragments 
The activity of inhibitor-l was measured by its 
ability to inhibit the phosphorylase phosphatase 
activity of protein phosphatase-1 [ 121. The reac- 
tions were carried out for only 5 min and initiated 
with protein phosphatase-1 rather than [3*P]phos- 
phorylase a. These precautions were taken to avoid 
prolonged incubation of inhibitor-l or its subfrag- 
ments with protein phosphatase-1, which might 
have caused significant dephosphorylation and in- 
activation of these peptides. However, control in- 
cubations demonstrated that the dephosphory- 
lation of each subfragment was negligible during 
the assays (< 5%). The specific radioactivity of in- 
hibitor-l and its subfragments was 20-50-fold 
56 
lower than that of [3*P]phosphorylase a, and ac- 
counted for < 1% of the QP-radioactivity in the 
assays. The inhibitory activity of all peptides was 
measured 2 5 times over a 2000-fold concentration 
range (from nM+M). 
2.4. Other analytical procedures 
Peptide mapping, gel filtration, amino,acid anal- 
ysis and automated sequencing were done as in [B]. 
3. RESULTS AND DISCUSSION 
The activities of peptide subfragments derived 
from inhibitor-l are given in table 2 and their 
structures are summarised in fig.2. The smallest 
peptide that was fully active was Llb comprising 
only 28% of the molecule (residues 9-54). 
However peptides Ll bA and LlcA, comprising 
residues 23-54 and 23-60 respectively, were inac- 
tive, as were peptides comprising residues 32-60 
or 32/33-69. Inhibitor-l as normally isolated is 
substantially phosphorylated on Ser67 [B]. This 
phosphoserine does not appear to be involved in 
the activity since the fragments that were fully ac- 
tive do not contain this residue. Furthermore a 
peptide comprising residues 6 l-71 was inactive 
(table 2). 
The results presented in table 2 and fig.2 dem- 
onstrate that the region comprising residues 9-22 
is essential for the activity of inhibitor- 1. The find- 
ing that a region not in the immediate vicinity of 
Thr35 is required for activity, is consistent with the 
kinetic studies that indicate inhibitor-l is not a 
competitive inhibitor [ 111. Interestingly. residues 
9-22 is the most hydrophobic region of inhibitor- 
1, a protein with a very low content of hydro- 
phobic amino acids IS]. Application of the predic- 
tions of Chou and Fasman [16] to the structure of 
inhibitor-l suggest that inhibitor-l contains a lim- 
ited amount of secondary structure (mostly /3- 
sheet) between residues 8-47, while the rest of the 
molecule contains little-ordered structure. These 
predictions are consistent with the results of circu- 
lar dichroism studies [13]. Thus the region that 
contains secondary structure can be equated with 
the active part of the protein. 
Peptides Ll b (residues 9-54) and L lc (9-60) 
were both fully active indicating that the hydro- 
phobic stretch from residues 55-60 (fig.2) is not 
required for activity. A chymotryptic peptide com- 
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CB-l 
UC 
LlU 
LUCA- 
pubA_ 
LTM31 
ILId, 
LChl, 
=Bl= =L2= 
=Thl--I 
Fig.2. N-Terminal 80 residues of inhibitor- 1 containing the active fragments CB- I, L 1 b and L lc: 
( I ) active fragments; ( 0 ) inactive fragments. 
prising residues 13-39/41 was completely inactive. question would require the isolation of peptides 
This might indicate that the region from residues comprising residues 9-41 and 13-54, but it has 
9-13 is crucial for activity, but it is perhaps more not yet proved possible to obtain a specific cleav- 
likely that some or all of the residues from 42-54 age between residues 41-54 without cleaving other 
are essential. The resolution of this important peptide bonds between residues 9-32 (table 2). 
Table 2 
Activities of the subfragments of inhibitor-l 
Digest Subfragment 
None 
Cyanogen bromide 
Lysine-specific 
proteinase I 
pH 2.9 hydrolysis 
of Llc 
of Llb 
Trypsin 
Lysine-specific 
proteinase 
Chymotrypsin 
Subtilisin 
Thermolysin 
Lysine-specific 
proteinase 
inhibitor-l 100 
CB-I lOOa 
Llc 100 
Llb 100 
LlcA 
LlbA 
TM3 
Lld 
Chl 
Bl 
Thl 
L2 
Activity 
(W) 
0.2 
0.1 
<O.l 
<O.l 
<O.l 
0.2 
O.lb 
co.1 
Position Size 
in sequence (residues) 
l-165 165 
2- 66 65 
9- 60 52 
9- 54 46 
23- 60 38 
23- 54 32 
32/33- 69 37-38 
32- 60 29 
13/17- 39/41 23-29 
29- 39 11 
29- 38 10 
61- 71 11 
aFrom [14]; bfrom [7] 
Peptides Llb, LlbA, Llc, LlcA, Chl and Bl were purified as in section 2, 
peptides CBl, TM3, and Lld as in (81 and Th-1 as in [7] 
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Further progress in defining the smallest active 
fragment of inhibitor-l would appear to depend 
on the chemical synthesis of appropriate phos- 
phopeptides. This would also allow interesting 
substitutions to be made, such as serine for 
threonine at position 35. It would additionally be 
of interest o examine the rates of phosphorylation 
and dephosphorylation of such fragments by cyclic 
AMP-dependent protein kinase and protein phos- 
phatases for which intact inhibitor-l is a substrate 
[11,17,18]. 
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